US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Release time：2024-05-21 23:26:50 Source：Culture Channels news portal
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
- Ravens sign WR Qadir Ismail, the son of former NFL receiver Qadry Ismail
- Chinese Woman Reaches Peak of Neuroscience Research
- 'Our Life Is the Best China Story'
- In Search of 'Treasures'
- FDIC chairman Martin Gruenberg to step down, White House says
- Leading a Village's Transformation
- Woman Photographer Captures Moments, Reflects Spirit of the Times
- Weifang: A City of Crafts and Folk Arts
- MPs' fury at 'virtue
- Attaining Wealth by Growing Popular Guavas
- Brewers starter Joe Ross leaves after first inning vs. Marlins with lower back strain
- Sheng: Ancestor of Free
- China Making Great Strides in Women's Cause
- Indian cyclists David Beckham, Ronaldo catch eyes at Asiad
- Pregnancy app used by the NHS accused of 'imposing gender ideology'
- 'Bethune in Daqing' Brings Light Back to Patients
- Chinese Woman Reaches Peak of Neuroscience Research
- Family of 'Red History' Takes Root in Jinggangshan
- Patrick Reed withdraws from US Open qualifying and ends streak of playing the majors
- Dessert Brand Reveals Sweet Tastes from Hutong
Random recommendation
- Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Culture Channels news portal sitemap